Loading...
Loading...
PYXS| Name | Value |
|---|---|
| Revenues | 3.4M |
| Cost of Revenue | 1.7M |
| Gross Profit | 1.7M |
| Operating Expense | 40.1M |
| Operating I/L | -40.1M |
| Other Income/Expense | 2.3M |
| Interest Income | 1.6M |
| Pretax | -37.7M |
| Income Tax Expense | -2.2M |
| Net Income/Loss | -35.6M |
Pyxis Oncology, Inc. is a preclinical stage biopharmaceutical company specializing in the development of immune-oncology therapies. Their product candidates include PYX-106, a siglec-15 targeting antibody for thyroid cancer, head and neck squamous cell carcinoma, NSCLC, and other solid tumors; PYX-102, an immune-therapeutic for solid tumors; and antibody drug conjugate (ADC) product candidates such as PYX-201, PYX-202, and PYX-203 for various cancer treatments.
